Abstract
Pharmacovigilance (PV) programs play a crucial role in improving drug usage patterns by detecting and reporting side effects. However, underreporting of ADRs remains a significant challenge, emphasizing the importance of healthcare professionals' involvement in the success of PV initiatives.